NZ619953A - Human cytomegalovirus neutralizing antibodies and use thereof - Google Patents

Human cytomegalovirus neutralizing antibodies and use thereof

Info

Publication number
NZ619953A
NZ619953A NZ619953A NZ61995309A NZ619953A NZ 619953 A NZ619953 A NZ 619953A NZ 619953 A NZ619953 A NZ 619953A NZ 61995309 A NZ61995309 A NZ 61995309A NZ 619953 A NZ619953 A NZ 619953A
Authority
NZ
New Zealand
Prior art keywords
seq
nos
heavy
amino acid
light chain
Prior art date
Application number
NZ619953A
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ619953(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Priority to NZ707788A priority Critical patent/NZ707788A/en
Publication of NZ619953A publication Critical patent/NZ619953A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A01D34/71—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis with means for discharging mown material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D2101/00—Lawn-mowers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed is an isolated antibody, or an antigen binding fragment thereof, wherein the antibody or fragment comprises (a) heavy and light chain variable regions having amino acid sequences set forth in SEQ ID NOs: 61 and 62, respectively, or heavy and light chain variable regions having amino acid sequences at least 85% identical to SEQ ID NOs: 61 and 62, respectively, or (b) heavy and light chain variable regions having amino acid sequences set forth in SEQ ID NOs: 29 and 30, respectively, or heavy and light chain variable regions having amino acid sequences at least 85% identical to SEQ ID NOs: 29 and 30, respectively, or (c) heavy and light chain variable regions having amino acid sequences set forth in SEQ ID NOs: 125 and 126, respectively, or heavy and light chain variable regions having amino acid sequences at least 85% identical to SEQ ID NOs: 125 and 126, respectively, wherein the sequences are as defined in the complete specification. Also disclosed is the use of said antibodies for the treatment of hCMV infection.
NZ619953A 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof NZ619953A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ707788A NZ707788A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8133408P 2008-07-16 2008-07-16
NZ60349909A NZ603499A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ619953A true NZ619953A (en) 2015-06-26

Family

ID=41550776

Family Applications (5)

Application Number Title Priority Date Filing Date
NZ707788A NZ707788A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof
NZ60349909A NZ603499A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and uses thereof
NZ591056A NZ591056A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof
NZ619953A NZ619953A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof
NZ60349809A NZ603498A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NZ707788A NZ707788A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof
NZ60349909A NZ603499A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and uses thereof
NZ591056A NZ591056A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ60349809A NZ603498A (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof

Country Status (31)

Country Link
US (21) US8603480B2 (en)
EP (3) EP3009449B1 (en)
JP (5) JP5422649B2 (en)
KR (1) KR101356350B1 (en)
CN (3) CN102203133B (en)
AU (1) AU2009272284C1 (en)
BR (1) BRPI0916443A2 (en)
CA (2) CA2730776C (en)
CL (3) CL2011000084A1 (en)
CO (1) CO6351801A2 (en)
CR (2) CR20160355A (en)
CU (1) CU23953B1 (en)
DK (2) DK3009449T3 (en)
EA (1) EA031177B1 (en)
EC (2) ECSP11010827A (en)
ES (2) ES2654543T3 (en)
GT (4) GT201100011CA (en)
HK (1) HK1220981A1 (en)
HN (1) HN2011000161A (en)
IL (7) IL210356A (en)
MA (1) MA32561B1 (en)
MX (5) MX338067B (en)
NZ (5) NZ707788A (en)
PE (7) PE20141433A1 (en)
PH (1) PH12015500782A1 (en)
PL (2) PL2352759T3 (en)
PT (2) PT2352759T (en)
SG (3) SG10201706350PA (en)
UA (1) UA106354C2 (en)
WO (1) WO2010007533A2 (en)
ZA (1) ZA201600335B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20141433A1 (en) 2008-07-16 2014-10-19 Inst Research In Biomedicine NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
EA201270662A1 (en) 2009-12-23 2013-01-30 4-Антибоди Аг BINDING ELEMENTS FOR HUMAN CYTAMEGALOVIRUS
AU2011268277B2 (en) * 2010-06-16 2016-10-27 Trellis Bioscience, Llc High affinity human antibodies to human Cytomegalovirus (CMV) gB protein
US20130171241A1 (en) 2010-07-06 2013-07-04 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
LT3243526T (en) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
ES2918649T3 (en) 2010-08-31 2022-07-19 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of RNA encoding an immunogen
CN103313727B (en) * 2010-09-29 2015-07-22 弗·哈夫曼-拉罗切有限公司 Antibody compositions and methods of use
BR112013008700B8 (en) 2010-10-11 2022-10-04 Novartis Ag SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
BR112014024023A2 (en) * 2012-03-28 2017-07-18 Genentech Inc anti-hcmv idiotypic antibodies and their uses
JP6419695B2 (en) 2012-07-27 2018-11-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ MVA vaccine for delivery of UL128 complex and prevention of CMV infection
WO2014028865A1 (en) * 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN104662044B (en) 2012-08-24 2018-10-30 加利福尼亚大学董事会 For treating ROR1 cancers and inhibiting the antibody and vaccine that shift
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3280441B1 (en) 2015-04-07 2021-09-29 Alector LLC Anti-sortilin antibodies and methods of use thereof
WO2017044895A2 (en) 2015-09-10 2017-03-16 City Of Hope MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
CN105296588A (en) * 2015-10-16 2016-02-03 常州市第一人民医院 Method for detecting harm degree of postoperative cytomegalovirus infection of kidney transplantation patient
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3426676A1 (en) 2016-03-11 2019-01-16 Pfizer Inc Human cytomegalovirus gb polypeptide
MA44723A (en) 2016-04-18 2019-02-27 Celldex Therapeutics Inc HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
EP3455251A4 (en) * 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof
AU2017289270B2 (en) 2016-06-27 2023-05-04 The Regents Of The University Of California Cancer treatment combinations
WO2018031903A1 (en) 2016-08-12 2018-02-15 Streck, Inc. Molecular reference controls
CN106519027B (en) * 2016-11-11 2019-09-17 深圳先进技术研究院 The full human monoclonal antibody 5J13 of anti-H7N9 and its preparation method and application
US11484570B2 (en) 2017-04-14 2022-11-01 University Of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
EP3612550A1 (en) 2017-04-19 2020-02-26 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
CN107325178A (en) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 A kind of anti-human cytomegalovirus Yolk antibody and its preparation method and application
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
KR20210011919A (en) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. Anti-CD27 antibody and anti-PD-L1 antibody and bispecific construct
CA3060547A1 (en) 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
EP3866845A1 (en) 2018-10-17 2021-08-25 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
CN109580944A (en) * 2018-12-07 2019-04-05 潍坊医学院 A kind of human cytomegalovirus Test paper and its manufacturing method
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (en) * 2019-01-21 2019-05-10 潍坊医学院 A kind of preparation method of human cytomegalovirus IgM antibody Test paper
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN112898414A (en) * 2019-12-04 2021-06-04 珠海泰诺麦博生物技术有限公司 Anti-human cytomegalovirus antibodies and uses thereof
US20230174626A1 (en) * 2020-03-27 2023-06-08 Glaxosmithkline Biologicals Sa Antibodies
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
WO2023034950A2 (en) * 2021-09-03 2023-03-09 Icahn School Of Medicine At Mount Sinai Anti-hcmv antibodies and antigen-binding fragments thereof
CN116162154A (en) * 2022-10-21 2023-05-26 珠海泰诺麦博生物技术有限公司 Anti-human cytomegalovirus antibodies and uses thereof
CN115947869B (en) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 Chimeric antigen receptor targeting human cytomegalovirus, CAR-NK cell and application

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) * 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) * 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
FR2543570B1 (en) 1983-03-31 1985-08-09 Pasteur Institut HUMAN ANTICYTOMEGALOVIRUS MONOCLONAL ANTIBODIES, SECRET HYBRIDOMAS THEREOF AND POLYPEPTIDES CARRYING A SEQUENTIAL ANTIGENIC DETERMINANT OF HUMAN CYTOMEGALOVIRUS
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (en) 1984-04-27 1988-02-19 Pasteur Institut ANTICYTOMEGALOVIRUS MONOCLONAL ANTIBODIES AND METHODS FOR THE IN VITRO DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS AND CYTOMEGALOVIRUS PROTEIN KINASE INFECTIONS WHICH CAN BE RECOGNIZED BY MONODOCONUS SUSPICY
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4950595A (en) 1984-09-28 1990-08-21 Teijin Limited Mouse-human hybridoma which produces antivirus-human antibody, process for preparation thereof, and antivirus-human monoclonal antibody
US4808518A (en) * 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
KR910000736B1 (en) 1985-12-06 1991-02-06 데이진 가부시키가이샤 Anticytomegalo virus human monoclonal antibody and process for its preparation
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (en) 1987-01-30 1988-08-23 Univ Bruxelles PROCESS FOR PRODUCING HUMAN MONOCLONAL ANTIBODIES (IGG) ANTICYTOMEGALOVIRUS AND MONOCLONAL ANTIBODIES THUS OBTAINED
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (en) 1990-11-06 1992-05-07 Biotest Ag METHOD FOR DETERMINING PROTEINS IN BODY LIQUIDS AND MEANS FOR IMPLEMENTING THE METHOD
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (en) 1991-06-26 1993-01-14 Green Cross Corp:The Cytomegalovirus-resistant human monoclonal antibody and cell for producing the same
DE4128684A1 (en) 1991-08-29 1993-03-04 Behringwerke Ag HCMV-SPECIFIC PEPTIDES, MEDIUM IN THIS AND THEIR USE
ATE173543T1 (en) 1992-04-10 1998-12-15 Thomas Totterman METHOD FOR DETECTING CMV INFECTION
SE9201281L (en) 1992-04-23 1993-10-24 Bioinvent Int Ab Novel human monoclonal antibodies and process for their preparation
JPH05260961A (en) 1992-05-21 1993-10-12 Teijin Ltd Hybridoma producing human monoclonal antibody against cytomegalovirus
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994016724A1 (en) 1993-01-21 1994-08-04 Zaia John A Prevention and treatment of cytomegalovirus using aminopeptidase
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
EP0683675A4 (en) 1993-01-28 1997-05-21 Sandoz Pharmaceuticals Corp Human monoclonal antibodies to cytomegalovirus.
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (en) * 1994-07-26 1997-01-15 Biotest Ag Polypeptides and fusion proteins that contain the UL57 open reading frame or the C-terminus of tegument protein pp150 from HCMV, corresponding oligonucleotides and diagnostic test kits
US5502652A (en) 1994-08-24 1996-03-26 Hoggatt; Austin C. Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
ATE225942T1 (en) 1996-07-12 2002-10-15 Organon Teknika Bv PEPTIDE REAGENT FOR DETECTION OF HUMAN CYTOMEGALOVIRUS (CMV)
AU728285C (en) 1996-08-14 2002-02-21 Wistar Institute Of Anatomy And Biology, The Methods and compositions for preventing or retarding the development of atherosclerotic lesions
US7504493B2 (en) * 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
US6156498A (en) 1997-01-30 2000-12-05 Cedars-Sinai Medical Center Establishment of HHV-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting HHV-8 infection
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
JP2001512662A (en) 1997-07-18 2001-08-28 コノート ラボラトリーズ リミテッド Nucleic acid vaccine encoding G protein of respiratory syncytial virus
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (en) 1997-12-17 1999-02-25 Biotest Ag New chimeric human cytomegalovirus (HCMV) polypeptides
AU754380B2 (en) 1998-03-12 2002-11-14 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
ATE249846T1 (en) 1998-06-29 2003-10-15 Wolfgang Bergter ANTIVIRAL AND ANTIRETROVIRAL RADIOIMMUNOPHARMACEUTICALS BASED ON ALPHA AND BETA EMPOWERS
RU2133472C1 (en) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Method for diagnosing active stage of human cytomegalovirus infection
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ATE488583T1 (en) 2001-02-21 2010-12-15 Wistar Inst RECOMBINANT VECTOR CONTAINING AN INFECTIOUS HUMAN CYTOMEGALOVIRUS GENOME WITH PRESERVED WILD-TYPE CHARACTERISTICS OF CLINICAL ISOLATE
ITMI20012160A1 (en) 2001-10-18 2003-04-18 Edoardo Marchisio IMMUNOENZYMATIC SYSTEM FOR THE ANTIGENIC CHARACTERIZATION OF THE ACTIVE INFECTION BY CYTOMEGALOVIRUS AND CMV CONFIRMATION TEST
CN1188427C (en) * 2001-12-07 2005-02-09 暨南大学 Recombinant chimeric peptide antigen detecting HCMV antibody and production method thereof
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
AU2002258689C1 (en) 2002-04-01 2008-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
DE10228103A1 (en) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungicidal active ingredient combinations
DE10232322A1 (en) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Virally encoded CxC determine the tissue tropism of HCMV
TWI270088B (en) 2002-11-29 2007-01-01 Furukawa Electric Co Ltd Insulated wire and resin dispersion
RU2239453C2 (en) 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Human immunoglobulin preparation against cytomegalovirus and method for its preparing
CN1445243A (en) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 Fab antibody of human resourced neutrality genetic engineering for anti human cytomegalo virus
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20040228842A1 (en) 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
WO2004078926A2 (en) * 2003-02-28 2004-09-16 Board Of Trustees Operating Michigan State University Immunologigal markers
CA2570823C (en) 2004-06-21 2015-02-24 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
CA2573090A1 (en) 2004-07-09 2006-01-19 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Differences in intestinal gene expression profiles
BE1016287A6 (en) 2004-07-14 2006-07-04 Picanol Nv SHAPE FORMING FOR A WEAVING MACHINE AND WEAVING MACHINE.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP2336174B8 (en) 2005-03-14 2015-09-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Human monoclonal antibodies against Hendra and Nipah viruses
BRPI0611707A2 (en) 2005-06-29 2012-04-24 Compumedics Ltd conductive bridge sensor assembly
JP5142458B2 (en) * 2005-06-30 2013-02-13 キヤノン株式会社 Target substance capture molecule, target substance capture element, target substance detection apparatus and kit using these, and target substance detection method
AU2006325236B2 (en) 2005-12-16 2011-11-10 Ribovax Biotechnologies Sa Methods for obtaining immortalized antibody secreting cells
WO2007094423A1 (en) 2006-02-15 2007-08-23 Evec Incorporated Human monoclonal antibody capable of binding to human cytomegalovirus, and antigen-binding domain of the antibody
CN101448951B (en) * 2006-05-19 2013-04-10 泰华制药工业有限公司 Fusion proteins, uses thereof and processes for producing same
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
RU2448979C2 (en) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
DK2126049T3 (en) * 2006-12-15 2011-07-18 Ribovax Biotechnologies Sa Human cytomegalovirus (hCMV) antibodies
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
US20110171233A1 (en) 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
CN102143974B (en) 2008-07-16 2015-03-25 生命医学研究学会 Human cytomegalovirus neutralising antibodies and use thereof
PE20141433A1 (en) 2008-07-16 2014-10-19 Inst Research In Biomedicine NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS

Also Published As

Publication number Publication date
US20160096880A1 (en) 2016-04-07
NZ603498A (en) 2014-02-28
US9796771B2 (en) 2017-10-24
US9725502B2 (en) 2017-08-08
HK1220981A1 (en) 2017-05-19
EA201170205A1 (en) 2011-08-30
US20170129940A1 (en) 2017-05-11
IL232865A0 (en) 2014-07-31
ECSP11010827A (en) 2011-07-29
ES2654543T3 (en) 2018-02-14
IL232865A (en) 2016-07-31
US20130302350A1 (en) 2013-11-14
IL232863A0 (en) 2014-07-31
US10414817B2 (en) 2019-09-17
US20120128692A1 (en) 2012-05-24
JP5422649B2 (en) 2014-02-19
SG10201608381SA (en) 2016-11-29
CN106924729A (en) 2017-07-07
JP6703037B2 (en) 2020-06-03
PE20140882A1 (en) 2014-07-25
CR20160355A (en) 2016-10-11
IL232861A0 (en) 2014-07-31
PE20141435A1 (en) 2014-10-22
JP2014087337A (en) 2014-05-15
KR101356350B1 (en) 2014-01-27
IL210356A0 (en) 2011-03-31
IL232863A (en) 2016-06-30
US9803000B1 (en) 2017-10-31
CL2011000084A1 (en) 2011-07-01
US20160280769A1 (en) 2016-09-29
AU2009272284B2 (en) 2012-04-05
US20160145319A1 (en) 2016-05-26
US20160280770A1 (en) 2016-09-29
PE20141433A1 (en) 2014-10-19
US8435524B2 (en) 2013-05-07
US20110268746A1 (en) 2011-11-03
GT201100011DA (en) 2017-09-20
US20120128691A1 (en) 2012-05-24
SG191699A1 (en) 2013-07-31
US20140205615A1 (en) 2014-07-24
US20100092481A1 (en) 2010-04-15
PE20141434A1 (en) 2014-10-22
ECSP11010826A (en) 2011-07-29
US20200017575A1 (en) 2020-01-16
US20130022618A1 (en) 2013-01-24
JP5807050B2 (en) 2015-11-10
CU23953B1 (en) 2013-10-29
US20170081391A1 (en) 2017-03-23
IL232862A0 (en) 2014-07-31
CA2730776A1 (en) 2010-01-21
AU2009272284A1 (en) 2010-01-21
US20140193428A1 (en) 2014-07-10
MX343490B (en) 2016-11-08
MX338067B (en) 2016-04-01
EP3009449A1 (en) 2016-04-20
ZA201600335B (en) 2017-11-29
MX343250B (en) 2016-10-31
MA32561B1 (en) 2011-08-01
US9527902B2 (en) 2016-12-27
JP6062477B2 (en) 2017-01-18
US9365636B1 (en) 2016-06-14
US9249213B2 (en) 2016-02-02
CN103980363B (en) 2017-04-12
US9371372B2 (en) 2016-06-21
US20150353627A1 (en) 2015-12-10
DK3009449T3 (en) 2018-08-06
SG10201706350PA (en) 2017-09-28
JP2018139611A (en) 2018-09-13
KR20110052585A (en) 2011-05-18
US9491906B2 (en) 2016-11-15
EP2352759B1 (en) 2017-11-01
PE20110413A1 (en) 2011-06-25
IL238421A (en) 2016-06-30
CN102203133B (en) 2015-01-07
US9221897B2 (en) 2015-12-29
AU2009272284C1 (en) 2014-05-15
CR20110091A (en) 2011-06-24
JP2017055765A (en) 2017-03-23
GT201100011BA (en) 2017-09-14
EP2352759A2 (en) 2011-08-10
US20180086819A1 (en) 2018-03-29
EP3009449B1 (en) 2018-06-06
CN102203133A (en) 2011-09-28
US20210087257A1 (en) 2021-03-25
WO2010007533A2 (en) 2010-01-21
US8298539B2 (en) 2012-10-30
IL232864A0 (en) 2014-07-31
US8124093B2 (en) 2012-02-28
CN106924729B (en) 2021-03-02
PL2352759T3 (en) 2018-04-30
EA031177B1 (en) 2018-11-30
CL2014001293A1 (en) 2014-12-05
DK2352759T3 (en) 2017-12-18
HN2011000161A (en) 2014-06-09
IL232864A (en) 2016-07-31
UA106354C2 (en) 2014-08-26
CA3022196A1 (en) 2010-01-21
NZ603499A (en) 2014-05-30
MX340315B (en) 2016-07-06
PT2352759T (en) 2018-01-08
GT201100011CA (en) 2017-09-14
PH12015500782A1 (en) 2015-12-14
NZ591056A (en) 2013-02-22
ES2682596T3 (en) 2018-09-21
US8603480B2 (en) 2013-12-10
US8765132B2 (en) 2014-07-01
US20170129939A1 (en) 2017-05-11
CL2016001340A1 (en) 2016-10-28
IL210356A (en) 2015-06-30
US10889632B2 (en) 2021-01-12
PE20141432A1 (en) 2014-10-18
PT3009449T (en) 2018-09-28
IL232861A (en) 2016-06-30
US20180371062A1 (en) 2018-12-27
NZ707788A (en) 2016-08-26
BRPI0916443A2 (en) 2017-10-31
CN103980363A (en) 2014-08-13
CO6351801A2 (en) 2011-12-20
IL232862A (en) 2016-06-30
WO2010007533A3 (en) 2010-08-12
MX2011000543A (en) 2011-04-27
US8287870B2 (en) 2012-10-16
JP6345753B2 (en) 2018-06-20
CU20110009A7 (en) 2012-06-21
JP2011527902A (en) 2011-11-10
US20170334972A1 (en) 2017-11-23
PL3009449T3 (en) 2018-09-28
CA2730776C (en) 2018-12-11
US10040845B2 (en) 2018-08-07
US9796772B2 (en) 2017-10-24
US9127049B2 (en) 2015-09-08
IL238421A0 (en) 2015-06-30
GT201100011AA (en) 2017-09-14
PE20141398A1 (en) 2014-10-18
JP2015145412A (en) 2015-08-13
WO2010007533A9 (en) 2017-08-10
EP3178845A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
NZ619953A (en) Human cytomegalovirus neutralizing antibodies and use thereof
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ703653A (en) Anti-fap antibodies and methods of use
NZ582150A (en) Antibodies to human programmed death receptor pd-1
NZ578844A (en) Human cytomegalovirus neutralising antibodies and use thereof
NZ595792A (en) Antibodies specific to cadherin-17
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ610734A (en) Human antibodies to the glucagon receptor
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ598063A (en) Gram-positive bacteria specific binding compounds
SI2579894T1 (en) Cgrp antibodies
NZ716762A (en) Specific binding proteins and uses thereof
NZ594682A (en) Fully human antibodies specific to cadm1
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
RS52782B (en) High affinity human antibodies to human il-4 receptor
NZ590891A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
MX2012000316A (en) Humanised antibodies to toll-like receptor 2 and uses thereof.
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ601271A (en) Cd127 binding proteins
NZ597692A (en) Anti-IGF antibodies
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
GEP20146050B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2016 BY AJ PARK

Effective date: 20160122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2017 BY CPA GLOBAL

Effective date: 20160603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2018 BY CPA GLOBAL

Effective date: 20170622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY CPA GLOBAL

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2020 BY CPA GLOBAL

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2021 BY CPA GLOBAL

Effective date: 20200618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20211110

LAPS Patent lapsed